JAMA Psychiatry Meta-Analysis Confirms Deprexis Efficacy
Hamburg, Germany, 27th February 2017 / Sciad Newswire / GAIA AG, a global pioneer in digital therapy, announced today that deprexis®, a web-based EC- and FDA-cleared medical device developed by GAIA, has once again been proven to be effective in a global scientific study.
A new meta-analysis of individual patient data, published in the latest issue of JAMA Psychiatry, confirmed the efficacy of deprexis® for the treatment of depression. The software is one of GAIA’s developments. It has recently been licensed to Servier globally, except for the US and Japan. The meta-analysis was a truly global collaborative effort, as 26 researchers from the Netherlands, the US, UK, Australia, Germany, Switzerland, and Spain combined data from 13 randomised controlled trials with a total of 3876 study participants. Of the 13 trials, 5 had examined deprexis® (38%), and 1199 of the participants came from deprexis® studies (31%). There were no other interventions from Germany. The average effect size reported for deprexis® studies was 0.53, compared to 0.28 for others.
“We are very pleased with the results of this meta-analysis. It confirms the results of previous randomised controlled trials (RCTs) on deprexis®,” added Mario Weiss, CEO and founder of GAIA. “Depression is a widely-spread pathology, with around 350 million people worldwide suffering from it (WHO). Patients benefit greatly from deprexis® as an adjunct therapy, in addition to pharmacologic or psychotherapeutic treatments.”
Ends
For further information, contact:
Mario Weiss
CEO and Founder, Gaia AG
E: info@gaia-group.com
T: +49 40 3510520
Got an innovation you need bringing to life?
We’d love to hear from you! Head to our contact page to start a conversation.
